ERBB2 and familial pancreatic carcinoma: We aimed to study tumor HER2 expression and its effects on T‐DM1 responses in patients with HER2‐positive urothelial bladder cancer (UBC) or pancreatic cancer (PC)/cholangiocarcinoma (CC).